Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAG-423 in severe preeclampsia
2018-004212-21Phase 2Terminated
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Mar 2019
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in preeclampsia comparing AMAG-423 with Placebo (2 arms). Started Mar 2019; status: terminated.
02
Drugs
AMAG-423
03
Conditions
preeclampsia
Beyond the preview
Go deeper on 2018-004212-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004212-21.